Get the Stockscreener App
6.63
2.07%
-0.14
After Hours:
6.62
-0.010
-0.15%
Optimizerx Corp stock is traded at $6.63, with a volume of 515.87K.
It is down -2.07% in the last 24 hours and up +1.07% over the past month.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
See More
Previous Close:
$6.77
Open:
$6.8
24h Volume:
515.87K
Relative Volume:
1.04
Market Cap:
$124.41M
Revenue:
$109.43M
Net Income/Loss:
$5.13M
P/E Ratio:
25.44
EPS:
0.2606
Net Cash Flow:
$18.91M
1W Performance:
+3.59%
1M Performance:
+1.07%
6M Performance:
-65.40%
1Y Performance:
-31.15%
1-Day Range:
$6.46
$6.8923
1-Week Range:
$5.95
$6.99
52-Week Range:
$5.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Name
Optimizerx Corp
Sector
Industry
Phone
248-651-6558
Address
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, BTSG, TEM, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
6.63 | 127.04M | 109.43M | 5.13M | 18.91M | 0.2606 |
VEEV
Veeva Systems Inc
|
171.19 | 27.80B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
51.44 | 10.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
54.07 | 10.01B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
82.63 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.77 | 4.60B | 637.78M | 239.40M | 307.21M | 1.1909 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Jul-25-24 | Resumed | B. Riley Securities | Buy |
| Apr-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Feb-02-23 | Resumed | B. Riley Securities | Buy |
| Nov-01-22 | Initiated | Stifel | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| Oct-18-21 | Resumed | B. Riley Securities | Buy |
| Apr-13-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-03-19 | Initiated | William Blair | Outperform |
View All
Optimizerx Corp Stock (OPRX) Latest News
OptimizeRx (OPRX) Projected to Post Earnings on Tuesday - MarketBeat
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline - Yahoo Finance
Are Investors Undervaluing OptimizeRx (OPRX) Right Now? - Yahoo Finance
OptimizeRx (OPRX) price target decreased by 40.41% to 14.79 - MSN
OPRX Technical Analysis & Stock Price Forecast - Intellectia AI
OPRX SEC FilingsOptimizerx Corp 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] OptimizeRx Corp SEC Filing - Stock Titan
OptimizeRx (OPRX) sets 2026 virtual meeting, equity plan expansion and pay votes - Stock Titan
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report - marketscreener.com
OptimizeRx (OPRX) soars 5.9%: Is further upside left in the stock? - MSN
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET - The Manila Times
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4: 30 p.m. ET - marketscreener.com
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 P.m. ET - Moomoo
OPRX OptimizeRx Corporation posts 120.6 percent Q4 2025 EPS surprise, shares rise modestly in today’s trading. - Newser
OptimizeRx (OPRX) Price Target Increased by 24.79% to 24.82 - MSN
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy? - TradingView
JMP Securities Maintains OptimizeRx (OPRX) Market Outperform Recommendation - MSN
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine? - TradingView
OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
New OptimizeRx Corp (OPRX) director registers insider status with Form 3 - Stock Titan
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds? - Yahoo Finance
OptimizeRx Corporation (OPRX) Stock Hits 52-Week High (Weakens) 2026-04-20Institutional Buying - Newser
How The OptimizeRx (OPRX) Narrative Is Shifting As Revenue Caution Meets Profit Optimism - Yahoo Finance
OPRX Trades at a Discount to Industry: How to Approach the Stock Now? - TradingView
Should Value Investors Buy OptimizeRx (OPRX) Stock? - Yahoo Finance
Medical robotics firm Myomo taps ex-OptimizeRx chief for board seat - Stock Titan
OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Growth in Short Interest - MarketBeat
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern? - qz.com
If You Invested $1,000 in Optimizerx Corp (OPRX) - Stock Titan
Whats the profit margin of OptimizeRx Corporation2026 Price Targets & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
OptimizeRx Corp. Receives Favorable Valuation Adjustment Amidst Profit Growth and High Institutional Confidence - Markets Mojo
OptimizeRx Adds Microsoft Health Leader to Board - TipRanks
OptimizeRx adds Microsoft Health exec to board of directors By Investing.com - Investing.com Australia
OptimizeRx adds Microsoft Health exec to board of directors - Investing.com
Microsoft health leader joins OptimizeRx (OPRX) board as independent director - Stock Titan
OptimizeRx Appoints Microsoft Health & Life Sciences COO to Board - National Today
OptimizeRx Appoints Mary Varghese Presti to Board of Directors - Bitget
OptimizeRx Taps Microsoft AI Leader for Board to Supercharge Growth - BriefGlance
Microsoft Health COO joins OptimizeRx board in director refresh - Stock Titan
List of 3 Acquisitions by OptimizeRx (Apr 2026) - Tracxn
Best Value Stocks to Buy for March 16th - Eastern Progress
What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now? - MSN
Optimizerx Corp Stock (OPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):